00:00Great, thank you Chris. It's truly an honor to be here today for this historic step forward to expand access to a class of medications that can fundamentally change the arc of chronic disease in our country. Of course these are the Incretan or GLP-1 agonist that we've been speaking about.
00:20For nearly 150 years, my company, Eli Lilly, has been investing in America. We've been advancing science and creating high value jobs. But today we, oh, are you okay? Gordon, are you okay?
00:34Yeah. Let's take a break.
Commenti